Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS ‐ AKI

BACKGROUND AND AIMS: Volume expansion with albumin is recommended to establish a diagnosis of hepatorenal syndrome-acute kidney injury (HRS-AKI). The optimal duration of albumin administration is debated and requires balancing the risk of overtreatment with the need for timely diagnosis and treatment. Therefore, this study aimed to compare the impact of different albumin treatment durations on terlipressin response and the prognosis of patients with HRS-AKI treated with terlipressin and albumin. METHODS: This multicenter, retrospective secondary analysis included patients with suspected HRS-AKI who were treated with terlipressin and albumin at 12 German centers. One hundred forty five patients were available for further analysis. The cohort was dichotomized into patients treated with albumin for < 24 h and for 24-60 h before initiation of terlipressin. Patients were followed for treatment response to terlipressin, need for haemodialysis (HD), survival, or liver transplantation (LT). RESULTS: Median MELD score of the cohort was 25 [IQR 21; 31]. During follow-up, 59 patients (40.7%) achieved a complete response to treatment with terlipressin, and 96 patients (66.2%) died or received an LT. Response rates to terlipressin therapy did not differ between albumin treatment groups (< 24 h vs. 24-60 h). In multivariable competing risk models, treatment duration of albumin was not associated with any response to terlipressin, considering death and LT as competing events. Of note, albumin treatment duration did not affect HD-/LT-free survival. CONCLUSION: Extending albumin treatment beyond 24 h had no impact on treatment response to terlipressin and albumin or HD-/LT-free survival in patients with HRS-AKI. CLINICAL TRIAL NUMBER: NCT06161766.

Authors

Institutions

Publication Details

Journal
Liver International
Published
2026-09-30
DOI
https://doi.org/10.1111/liv.70888
Primary Topic
Trauma, Hemostasis, Coagulopathy, Resuscitation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS ‐ AKI

Paul Jamme, Christoph Welsch, Moritz Passenberg, Jassin Rashidi‐Alavijeh et al.
Liver International
Trauma, Hemostasis, Coagulopathy, Resuscitation
article

Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS ‐ AKI

Paul Jamme, Christoph Welsch, Moritz Passenberg, Jassin Rashidi‐Alavijeh, Christian Labenz, Marcus Maximilian Mücke, Nina Böhling, Jonel Trebicka, Julian Cardinal von Widdern, Cornelius Engelmann, Julian Pohl, Dominik Bettinger, Cristina Ripoll, Frank Erhard Uschner, Michael Praktiknjo, Marlene Reincke, Eva Maria Schleicher, Henrik Karbannek, Sarah Schütte, Karsten Große, the German cirrhosis study group
article en

Abstract

BACKGROUND AND AIMS: Volume expansion with albumin is recommended to establish a diagnosis of hepatorenal syndrome-acute kidney injury (HRS-AKI). The optimal duration of albumin administration is debated and requires balancing the risk of overtreatment with the need for timely diagnosis and treatment. Therefore, this study aimed to compare the impact of different albumin treatment durations on terlipressin response and the prognosis of patients with HRS-AKI treated with terlipressin and albumin. METHODS: This multicenter, retrospective secondary analysis included patients with suspected HRS-AKI who were treated with terlipressin and albumin at 12 German centers. One hundred forty five patients were available for further analysis. The cohort was dichotomized into patients treated with albumin for < 24 h and for 24-60 h before initiation of terlipressin. Patients were followed for treatment response to terlipressin, need for haemodialysis (HD), survival, or liver transplantation (LT). RESULTS: Median MELD score of the cohort was 25 [IQR 21; 31]. During follow-up, 59 patients (40.7%) achieved a complete response to treatment with terlipressin, and 96 patients (66.2%) died or received an LT. Response rates to terlipressin therapy did not differ between albumin treatment groups (< 24 h vs. 24-60 h). In multivariable competing risk models, treatment duration of albumin was not associated with any response to terlipressin, considering death and LT as competing events. Of note, albumin treatment duration did not affect HD-/LT-free survival. CONCLUSION: Extending albumin treatment beyond 24 h had no impact on treatment response to terlipressin and albumin or HD-/LT-free survival in patients with HRS-AKI. CLINICAL TRIAL NUMBER: NCT06161766.

Liver InternationalVol. 46(11)
Goethe University Frankfurt (DE), University of Münster (DE), University Hospital Bonn (DE), University Medical Center Freiburg (DE), LMU Klinikum (DE), Medizinische Hochschule Hannover (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), University Hospital Münster (DE), Universitätsklinikum Aachen (DE), University Hospital Frankfurt (DE), Jena University Hospital (DE), University of Duisburg-Essen (DE), Martin Luther University Halle-Wittenberg (DE), Charité - Universitätsmedizin Berlin (DE), Ludwig-Maximilians-Universität München (DE), RWTH Aachen University (DE)
Good health and well-being
Openalex Percentile: Top 10%
Trauma, Hemostasis, Coagulopathy, Resuscitation
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.